The role of wide-spectrum cytokeratin staining of the bone marrow cores in patients with ductal carcinoma of the breast.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 9005447.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The usefulness of routine pancytokeratin staining of bone marrow cores (BMCs)--negative for hematoxylin and eosin (HE)--from patients with lobular carcinoma of the breast has been fairly well established. However, the role of wide-spectrum cytokeratin staining of HE-negative BMCs from patients with ductal carcinoma has not been as well determined and is the purpose of this study. Forty-two prospectively and retrospectively reviewed He-negative BMCs from 21 patients with ductal breast carcinoma failed to reveal staining with a wide-spectrum cytokeratin stain, supporting the selective use of this immunostain in "suspicious" cases with atypical cells detected in HE BMCs.
Medical subject headings
- Biomarkers, Tumor
- Bone Marrow
- Bone Marrow Neoplasms
- Breast Neoplasms
- Carcinoma, Ductal, Breast
- Keratins